SCHEMBL25834990

SCHEMBL25834990

CC(C)OCCCC(=O)NCCOCCOCCOCCOc1ccc(-c2nnc(S(C)(=O)=O)o2)cc1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.41
MAPT P10636 2/20 0.40
ALOX15 P16050 2/20 0.40
TSHR P16473 1/20 0.40
HPGD P15428 2/20 0.39
NR1H4 Q96RI1 1/20 0.38
GAA P10253 1/20 0.38
KMT2A Q03164 2/20 0.38
CYP3A4 P08684 2/20 0.37
RAB9A P51151 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
SMPD1 P17405 1/20 0.37
POLB P06746 1/20 0.37
TP53 P04637 1/20 0.37
NCF1 P14598 1/20 0.36
MEN1 O00255 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26034354 0.86 ATM (0.43) ATMMAPTALOX15TSHRHPGD
SCHEMBL25834954 0.86 ATM (0.43) ATMMAPTALOX15TSHRHPGD
SCHEMBL25834864 0.84 TP53 (0.42) ATMMAPTALOX15TSHRHPGD
SCHEMBL25836356 0.80 MAPT (0.37) MAPTALOX15TSHRGAARAB9A
SCHEMBL25836929 0.80 ATM (0.45) ATMMAPTALOX15TSHRHPGD
SCHEMBL25839775 0.79 RECQL (0.47) MAPTALOX15TSHRHPGDRAB9A
SCHEMBL25834992 0.78 ALDH1A1 (0.46) MAPTTSHRHPGDNR1H4RAB9A
SCHEMBL25834802 0.77 ATM (0.45) ATMMAPTALOX15TSHRHPGD
SCHEMBL24340791 0.77 MTNR1A (0.51) MAPTALOX15TSHRHPGDNR1H4
SCHEMBL31671373 0.76 ALDH1A1 (0.44) MAPTTSHRHPGDNR1H4GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230265429-A1 SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF Arrowhead Pharmaceuticals, Inc. 2023-08-24 US disclosed
US-20230226193-A1 LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS Arrowhead Pharmaceuticals, Inc. 2023-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230226193-A1 LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS CPT1B, MUSK, MYLK2 ATM 2852/4885MAPT 3973/4885ALOX15 1471/4885
US-20230265429-A1 SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF MUSK, MYLK2, TNNC1 ATM 2775/4885MAPT 4094/4885ALOX15 4619/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.